Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-121 subcutaneous in adults with primary IgA nephropathy
2026-525638-43-00Phase 2Authorised
- Sponsor
- argenx
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 2, randomised trial in IgA nephropathy (IgAN) comparing ARGX-121 SC with Placebo matching ARGX-121 (2 arms). Primary endpoint: Change in proteinuria from baseline to Week 24. Planned start Oct 2026; status: authorised.
02
Drugs
ARGX-121
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2026-525638-43-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525638-43-00.